|
Intelligent surveillance can help pharma companies act before local crises damage global brands.
May 1, 2002
By:
Simon Titley, Ilyssa Levins
Surprises may be good for birthday parties, but when it comes to pharma marketing, global companies with US headquarters need to know what to expect from European markets. Whether they face stiff competition for blockbuster products; are involved in acquisitions, mergers, or litigation; or are monitoring the European Commission's (EC) decision making process, global pharma marketers must be aware of negative buzz that might affect their global brands.
|